Tumor News and Research

RSS

New study on pancreatic cancer survival

Pancreatic cancer is one of the deadliest and most difficult to treat cancers. Now, in a major step forward, researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have shown that administering radiation therapy prior to surgery nearly doubles survival in pancreatic cancer patients with operable tumors.

25 Nov 2008

Novel device enhances efficacy of standard chemotherapy

NovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients.

24 Nov 2008

Discovery of novel approach to suppress prostate cancer progression

Researchers at the University of Southern California (USC) have found that inactivating a specific biomarker for aggressive prostate cancer blocks the development of prostate cancer in animal models.

24 Nov 2008

Brookhaven scientists receive patent for improved cancer therapy device

Four physicists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory have been awarded U.S. Patent No. 7,432,516 B2 for the design of a "medical synchrotron" capable of delivering precision doses of proton radiation to cancerous tumors with minimal damage to surrounding healthy tissue.

24 Nov 2008

Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer

Medarex, Inc. has announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer.

24 Nov 2008

Hospital admissions for lung cancer stable

Hospital admissions for lung cancer remained relatively stable - at roughly 150,000 a year between 1995 and 2006 - despite a steady decline in the number of Americans diagnosed with the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

24 Nov 2008

New model predicts risk of recurrence in early stage colon cancer patients

Researchers in the Duke Institute for Genome Sciences & Policy have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens.

24 Nov 2008

New approach to stopping germs

Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.

20 Nov 2008

Epeius Biotechnologies announces results of Rexin-G in chem-resistant metastatic soft tissue sarcoma and osteosarcoma

Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008.

20 Nov 2008

Possible new target for anticancer therapeutics

New data, generated in mice, by Pierre Sonveaux and colleagues, at University catholique de Louvain, Belgium, have identified a potential new target for anticancer therapeutics.

20 Nov 2008

Lactic acid found to be important energy source for tumor cells

Many tumors have cells that burn fuel for activities in different ways. Tumor cells near blood vessels have adequate oxygen sources and can either burn glucose like normal cells, or lactic acid (lactate). Tumor cells further from vessels are hypoxic and inefficiently burn a lot of glucose to keep going. In turn, they produce lactate as a waste product.

20 Nov 2008

Researchers reveal a new aspect of tumor development

The DNA in our cells is constantly under assault from oxygen, the sun's radiation and environmental stresses.

20 Nov 2008

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.

20 Nov 2008

Bionovo to present phase 1B trial results of BZL101 in metastatic breast cancer

Bionovo, Inc. has announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth International Conference in Atlanta, Georgia.

20 Nov 2008

Targeted nanoparticles boost platinum-based anticancer therapy

A research team from the Massachusetts Institute of Technology (MIT)-Harvard Center for Nanotechnology Excellence has custom-designed nanoparticles that can deliver the anticancer drug cisplatin specifically to prostate cancer cells.

20 Nov 2008

Nanoparticle reports on drug delivery to breast tumors, predicts response to therapy

One of the hallmarks of many nanoparticle-based anticancer therapeutics and imaging agents is that they accumulate in tumors thanks to the fact that they are small enough to escape from the bloodstream through the leaky blood vessels that surround tumors.

20 Nov 2008

Nanoparticle targets melanoma with siRNA

Research has shown that a particular receptor for the blood protein thrombin is overexpressed by highly metastatic melanoma cells.

20 Nov 2008

New compounds break up cancer-causing protein STAT3 and destroy breast cancer tumors.

Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.

19 Nov 2008

Survival of head and neck cancer patients is greatly affected by coexisting ailments

Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital.

19 Nov 2008